Morningstar Investment Services LLC Boosts Stake in Gilead Sciences, Inc. (GILD)
Morningstar Investment Services LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 23.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,338 shares of the biopharmaceutical company’s stock after buying an additional 12,774 shares during the period. Morningstar Investment Services LLC’s holdings in Gilead Sciences were worth $4,837,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of GILD. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares in the last quarter. Penserra Capital Management LLC increased its position in Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. Webster Bank N. A. increased its position in Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the last quarter. American Beacon Advisors Inc. acquired a new stake in Gilead Sciences during the first quarter worth about $143,000. Finally, Welch Group LLC increased its position in Gilead Sciences by 9.7% during the first quarter. Welch Group LLC now owns 2,857 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 252 shares during the last quarter. 73.97% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 79.95 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The stock has a market cap of $104.41 billion, a P/E ratio of 8.68 and a beta of 1.14. The stock’s 50 day moving average is $82.48 and its 200 day moving average is $72.25.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter last year, the company earned $3.08 earnings per share. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.60%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s payout ratio is currently 22.58%.
Several research firms recently issued reports on GILD. Jefferies Group LLC restated a “hold” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 11th. BMO Capital Markets restated an “outperform” rating and set a $82.00 price objective (up from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Robert W. Baird restated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a research report on Thursday, July 13th. J P Morgan Chase & Co restated an “overweight” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 4th. Finally, BidaskClub upgraded shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Twelve research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $85.80.
ILLEGAL ACTIVITY WARNING: “Morningstar Investment Services LLC Boosts Stake in Gilead Sciences, Inc. (GILD)” was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/morningstar-investment-services-llc-boosts-stake-in-gilead-sciences-inc-gild/1635619.html.
In related news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now directly owns 3,199,969 shares in the company, valued at $242,749,648.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Insiders have sold 486,819 shares of company stock valued at $39,298,919 in the last three months. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.